UNITED STATES
                    SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549


                                 FORM 8-K

                              CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 2, 2004

                  CareDecision Corporation. (OTCBB: CDED)
            (Exact name of Registrant as specified in charter)


             Nevada              000-33187           91-2105842
 (State or other jurisdiction   (Commission       (I.R.S. Employer
       of incorporation)        File Number)       Identification)


 2660 Townsgate Road, Suite 300, Westlake Village, CA         91361
      (Address of principal executive offices)              (Zip Code)


 Registrant's telephone number, including area code:    (805) 446-1973


/1/


ITEM 7.01 REGULATION FD DISCLOSURE

CareDecision  Corporation ("CareDecision" or the  "Company")
[OTCBB:  CDED]  announced December  8,  2004  that  we  have
secured a $10 million monthly revolving credit facility that
includes  standby provisions for increases  to  $15  million
monthly.   This  facility, issued by WSSMF, LP  and  Capital
Growth  Fund,  two  financial  lending  institutions,   will
facilitate  the purchase of FDA-approved pharmaceutical  and
diagnostic  products, which will be sold through  our  newly
acquired  wholesale pharmacy distribution networks and  will
be applied to our new e-pharmacy.  Both Pharma channels will
employ our patent pending wireless PDA technologies.

The  credit  facility agreement closed on December  2,  2004
concurrent  with  the  completion  of  our  recent   merger.
CareDecision through our subsidiary company has concluded  a
merger  agreement with CareGeneration, Inc.  ("CGI").   This
agreement  includes  CGI's  recent  acquisition  of  certain
assets  and  the  transfer  of  pharmaceutical  distribution
licenses  from the Kelly Co. World Group, Inc.  (the  "Kelly
Companies").  Management believes the final closing of these
mergers, through the filing of merger certificates with  the
Nevada Secretary of State, should occur after a statutory 20
day  notice  period.  At that time, we will take  the  steps
necessary to rename the newly combined company "Next GENeSYS
Corp."  We believe that our access to growth capital coupled
with  the additional revenue streams provided by the mergers
positions us well to embark on our mission to link uninsured
and    underinsured   Americans   with    life    preserving
pharmaceuticals  by utilizing our wireless  technology,  our
pharmaceutical   distribution  network  and   our   industry
connections.



Date: December 8, 2004.
      -----------------


CareDecision Corporation


/s/ Keith Berman
----------------
Keith Berman, CFO


/2/